Condition

Hormone Receptor Positive Breast Carcinoma clinical trials and research

• 15Clinical trials
• 21Countries

Newest Hormone Receptor Positive Breast Carcinoma clinical trials

All recruiting trials (15)

• Tai Chi for joint pain relief in women on aromatase inhibitors

  This pilot study tests whether a Tai Chi program called TaiChi4Joint can help reduce AI-induced arthralgia in postmenopausal women with hormone receptor-positive breast cancer.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07737951

• AVA6103 for advanced or metastatic FAP-positive solid tumors

  This study will test whether the experimental IV drug AVA6103 is safe and can help adults with advanced or metastatic FAP-positive cancers such as pancreatic, gastric/GEJ, cervical, or vulvar adenocarcinomas.

  Recruiting at 7 sites Phase 1 Avacta Life Sciences Ltd · Scottsdale, Arizona and 6 other locations · NCT07454642

• Sleep Changes and Biomarkers After Breast Cancer Treatment

  This project will see how sleep patterns and stress-related biological markers change from treatment through survivorship in people with stage I–III hormone receptor–positive breast cancer.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07341503

• 5-strain probiotic to prevent bone loss during aromatase inhibitor therapy

  This trial will try a 5-strain probiotic called WBF-038 to see if it prevents bone loss in people with early-stage hormone receptor–positive breast cancer who are starting aromatase inhibitor therapy.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07044310

• Revaree Plus for vaginal dryness in people with breast cancer

  This trial will test whether Revaree Plus can improve vaginal dryness and related discomfort in adults with hormone-receptor–positive stage 0–III breast cancer who are on tamoxifen, aromatase inhibitors, or SERMs.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07042581

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Using acupuncture and acupressure to reduce joint pain in Black women with early-stage breast cancer

  This study is testing whether acupuncture and virtual acupressure can help reduce joint pain for Black women with early-stage breast cancer who are taking hormone therapy.

  Recruiting at 4 sites Emory University · Atlanta, Georgia and 3 other locations · NCT06534125

• Trastuzumab deruxtecan versus CDK4/6 inhibitor plus hormone therapy as first-line treatment for HR-positive, HER2-low non-luminal advanced breast cancer.

  This trial will see if trastuzumab deruxtecan (T-DXd) works better than a CDK4/6 inhibitor plus endocrine (hormone) therapy as first-line treatment for adults with HR-positive, HER2-low advanced breast cancer that is classified as non-luminal by gene profiling.

  Recruiting at 79 sites Phase 2 MedSIR · Graz and 78 other locations · NCT06486883

• Measuring a biomarker for breast cancer treatment effectiveness

  This study is testing if measuring a specific biomarker can help doctors understand how well hormone treatments are working for people with advanced breast cancer.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06388122

• ARX788 for HER2-low breast cancer

  This phase 2 study tests ARX788 as a single-drug treatment for adults with HER2-low locally advanced unresectable or metastatic breast cancer.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT06224673

• BGB-43395 treatment for advanced breast cancer and other solid tumors

  This study is testing a new treatment called BGB-43395 for people with advanced breast cancer and other solid tumors to see if it works better alone or with other medications.

  Recruiting at 57 sites Phase 1 BeOne Medicines · Denver, Colorado and 60 other locations · NCT06120283

• Combining an immunotherapy drug with standard chemotherapy for advanced breast cancer

  This study is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy can help people with advanced hormone receptor-positive, HER2-negative breast cancer live longer and feel better.

  Recruiting at 552 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 564 other locations · NCT06058377

• Combining letrozole and simvastatin to treat hormone receptor positive breast cancer

  This study tests if combining letrozole with simvastatin can help shrink tumors in postmenopausal women with hormone receptor positive breast cancer better than using letrozole alone.

  Recruiting at 4 sites Early Phase 1 Emory University · Atlanta, Georgia and 3 other locations · NCT05464810

• Treatment for early-stage HER2 low, hormone receptor positive breast cancer

  This study is testing whether a new treatment combining trastuzumab deruxtecan and anastrozole can help people with early-stage HER2 low, hormone receptor positive breast cancer do better than just using trastuzumab deruxtecan alone.

  Recruiting at 7 sites Phase 2 Jonsson Comprehensive Cancer Center · Fullerton, California and 8 other locations · NCT04553770

• Using abemaciclib to treat older patients with hormone receptor positive breast cancer

  This study is testing if the medication abemaciclib can safely help older patients with hormone receptor positive breast cancer feel better and live longer.

  Recruiting at 6 sites Phase 2 City of Hope Medical Center · Duarte, California and 5 other locations · NCT04305834

Related topics

Quick answers

How many Hormone Receptor Positive Breast Carcinoma clinical trials are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (13 trials), France (2 trials), Italy (2 trials), Austria (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1: 2, Phase 3: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →